Search research articles
Contact Us
Filters
Showing results (71-80 of 92) with videos related to
Page
of 10
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 6, 2026
Combination of Lurbinectedin plus Irinotecan: Preclinical and Early Clinical Results in Relapsed Small Cell Lung Cancer Patients
Santiago Ponce, Miguel Ruiz-Torres, Alejandro Falcón, et al.
Cell
|
February 7, 2025
GUK1 activation is a metabolic liability in lung cancer
Jaime L Schneider, Kiran Kurmi, Yutong Dai, et al.
Cancer Discovery
|
December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Alexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Nature Communications
|
May 2, 2025
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
Chendi Li, Mohammed Usman Syed, Anahita Nimbalkar, et al.
Cancer Discovery
|
April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer
Satoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 12, 2023
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, et al.
Cancer Discovery
|
September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
JCO Precision Oncology
|
December 22, 2025
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) Fusions
Tejas Patil, Jessica J Lin, Parneet K Cheema, et al.
JCO Precision Oncology
|
October 30, 2018
Clinical Utility of Rapid <i>EGFR</i> Genotyping in Advanced Lung Cancer
Ibiayi Dagogo-Jack, Christopher G Azzolli, Florian Fintelmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer
Jessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 92) with videos related to
Sort By:
Page
of 10
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 6, 2026
Combination of Lurbinectedin plus Irinotecan: Preclinical and Early Clinical Results in Relapsed Small Cell Lung Cancer Patients
Santiago Ponce, Miguel Ruiz-Torres, Alejandro Falcón, et al.
Cell
|
February 7, 2025
GUK1 activation is a metabolic liability in lung cancer
Jaime L Schneider, Kiran Kurmi, Yutong Dai, et al.
Cancer Discovery
|
December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Alexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Nature Communications
|
May 2, 2025
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
Chendi Li, Mohammed Usman Syed, Anahita Nimbalkar, et al.
Cancer Discovery
|
April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer
Satoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 12, 2023
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, et al.
Cancer Discovery
|
September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
JCO Precision Oncology
|
December 22, 2025
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) Fusions
Tejas Patil, Jessica J Lin, Parneet K Cheema, et al.
JCO Precision Oncology
|
October 30, 2018
Clinical Utility of Rapid <i>EGFR</i> Genotyping in Advanced Lung Cancer
Ibiayi Dagogo-Jack, Christopher G Azzolli, Florian Fintelmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung Cancer
Jessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
Page
of 10